Nivolumab for Esophageal Cancer: An Interview With Ken Kato, MD, PhD

Results from a phase 3 trial show that nivolumab significantly improves overall survival compared with chemotherapy in patients who have been previously treated for advanced esophageal squamous cell carcinoma (ESCC). In this interview with i3 Health, Ken Kato, MD, PhD, explains the results from this study, as well as rationale for using nivolumab in ESCC, safety considerations, and the study's implications for oncology practice.What is the most challenging aspect of treating patients with advanc...
Continue reading

Veliparib Adds Benefits to Ovarian Carcinoma Treatment: An Interview With Robert L. Coleman, MD

High-grade serous ovarian carcinoma is the most malignant form of ovarian cancer, with a high recurrence rate and a low survival rate. While patients are commonly treated with induction chemotherapy consisting of paclitaxel plus carboplatin, there is a need to develop additional first- and second-line therapies to increase survival in patients with this disease.In their study now published in The New England Journal of Medicine, Robert L. Coleman, MD, a Professor in the Department of Gynecologic...
Continue reading

Treating Multiple Myeloma: Challenges, Solutions, and Research Advances With Carol Ann Huff, MD

​With a five-year survival rate of only 50.7%, multiple myeloma remains difficult to treat. In this interview with i3 Health, Carol Ann Huff, MD, Medical Director for the Johns Hopkins Kimmel Cancer Center, explores the challenges and research advances of myeloma treatment. She also gives advice on helping patients to find assistance with the prohibitive costs of treatment and on handling the difficulties involved in treating patients at smaller community cancer centers, including patients who l...
Continue reading

Epidermal Growth Factor Ointment for Skin Toxicities: An Interview With Sung Yong Oh, MD, PhD

By inhibiting epidermal growth factor receptor (EGFR) signaling pathways, EGFR inhibitors have shown efficacy in the treatment of a variety of cancers, including non-small cell lung cancer (NSCLC), pancreatic cancer, and colorectal cancer. However, most patients who receive EGFR inhibitors develop adverse skin events, such as acneiform rash, xerosis, paronychial inflammation, pruritis, photosensitivity, and hair and eyelash alteration. If not properly managed, these toxicities can lead to physic...
Continue reading

When Should Ruxolitinib Be Used for Myelofibrosis or PV? With Srdan Verstovsek, MD, PhD

Myelofibrosis, a rare myeloproliferative neoplasm, can cause severe anemia, splenomegaly, and debilitating symptoms. It can present either as a primary condition or as a secondary condition following the transformation of essential thrombocythemia or polycythemia vera (PV), a slow-growing blood cancer in which the bone marrow produces an excess of red blood cells and often of white blood cells and platelets. Last week at the Society of Hematologic Oncology (SOHO)'s Seventh Annual Meeting, Srdan ...
Continue reading

Copyright © 2020 i3 Health. All rights reserved.